In adults with primary hypercholesterolaemia (heterozygous familial and non‑familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL‑C goals with the maximum tolerated dose of a statin; or,
  • alone or in combination wtih other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statis is contraindicated.

Medicine details

Medicine name:
bempedoic acid (Nilemdo)
Pharmaceutical company
Daiichi Sankyo UK Ltd
Submission type
Publication due date:
07 December 2020
SMC meeting date:
03 November 2020
Patient group submission deadline:
05 October 2020